Revenio Group’s €290 million acquisition of Visionix has broadened its eye-care technology portfolio, while a new partnership between iCare and EyeCheq aims to bring earlier screening closer to patients across the United States.
Revenio Group is strengthening its position in the global eye-care market through a combination of acquisition, technology integration and expanded access to screening. Following the completion of its €290 million acquisition of Visionix, Revenio’s iCare business has entered a strategic partnership with EyeCheq to support the rollout of point-of-care eye screening across the US. The partnership includes a minority investment in EyeCheq and combines iCare’s ophthalmic imaging technology with EyeCheq’s community-based screening model. The goal is to make early eye-disease detection more accessible in pharmacies, health clinics, laboratories and primary-care facilities.
Bringing eye screening closer to patients
EyeCheq screening stations will integrate iCare’s DRSplus fundus-imaging technology alongside additional ophthalmic devices.The stations are designed to screen for three major causes of sight loss:
- Diabetic retinopathy
- Glaucoma
- Age-related macular degeneration
Instead of requiring patients to start their care journey in a specialist ophthalmology or optometry practice, the model brings retinal screening into everyday healthcare settings where people are already receiving other services. This approach could help identify individuals at risk of eye disease before symptoms appear or routine eye care is accessed.
Clinician-reviewed results within 24 hours
Images captured through EyeCheq stations will be reviewed by licensed optometrists and ophthalmologists. Patients are expected to receive a personalised report and follow-up guidance within 24 hours, creating a faster link between initial screening and appropriate clinical care. This combination of accessible image capture and remote clinical review may streamline the pathway from early detection to referral, while ensuring qualified eye-care professionals remain central to interpretation and next-step decisions. Pilot deployments of the screening model are already underway in the US.
Revenio expands its eye-care technology portfolio
The partnership follows Revenio Group’s acquisition of Visionix, completed in May 2026 at an enterprise value of €290 million. The transaction brought Visionix together with Revenio’s existing iCare business, forming a combined group with capabilities spanning:
- Fundus imaging
- Optical coherence tomography
- Tonometers and perimeters
- Refraction systems
- Multimodal diagnostic platforms
- Clinical software and connected workflows
Revenio said the combined businesses represent more than €250 million in illustrative 2025 sales, €48 million in adjusted EBITDA and over 800 employees. The acquisition also expands Revenio’s presence across ophthalmology, optometry and optical retail, while accelerating its entry into the OCT market.
From broader technology to wider access
The Visionix acquisition and EyeCheq partnership represent two connected elements of Revenio’s growth strategy. Visionix strengthens the group’s diagnostic, imaging, refraction and software capabilities. EyeCheq adds a new route for deploying eye-screening technology beyond specialist practices and closer to patients. For the eye-care sector, the development reflects a broader shift towards decentralised screening, connected diagnostic systems and earlier intervention. It also underscores a key distinction between screening and diagnosis. Technology can make initial assessments more convenient and scalable, but clinical interpretation, referral and ongoing care remain essential parts of the pathway.
Could point-of-care screening reshape the eye-care pathway?
Making retinal imaging available in pharmacies, laboratories and primary-care facilities could help providers reach populations that might otherwise go unscreened. The longer-term impact will depend on how effectively these services connect patients with local optometrists and ophthalmologists when further assessment or treatment is needed. For Revenio Group, iCare, Visionix and EyeCheq, the strategy is clear: combine a broader ophthalmic technology portfolio with new delivery models that make early eye screening more accessible across the US. As point-of-care screening expands, the opportunity is not only to detect potential disease earlier, but also to ensure that every screening result leads to appropriate professional care.